HK Stock Market Move | DOBOT (02432) falls by nearly 5% again, planning to offer a discount of 10% for additional share placement, raising a net fund of HK$770 million to increase investment in product research and development and expand industrial chain layout.
Yue Xiang (02432) dropped nearly 5% again, with a decrease of 4.42% as of press time, closing at HKD 45.88, with a turnover of HKD 65.44 million.
DOBOT (02432) fell nearly 5%, at the time of publication, it dropped 4.42% to HK$45.88, with a turnover of HK$65,443,700.
On the news front, DOBOT announced that it plans to issue 16.66 million new H shares at a price of HK$46.80 per share, a discount of 10.3% from the closing price of HK$52.20 on November 5. The net proceeds from this placement are approximately HK$771 million. 40% will be used to advance the technological research and product innovation of Smart Siasun Robot & Automation; 20% will be used to seek investment, acquisitions, and strategic alliance opportunities in the value chain and adjacent areas of Siasun Robot & Automation; 20% will be used to strengthen the group's sales channels domestically and internationally, and further increase marketing efforts; 20% will be used to supplement operating funds and for general corporate purposes.
It is worth noting that Lens Technology and DOBOT have officially signed a deep strategic cooperation agreement in Shenzhen. According to the agreement, Lens Technology will purchase 1,000 Smart Siasun Robot & Automation units from DOBOT by 2025. At the same time, DOBOT has also placed an order with Lens Technology for 10,000 units of quadruped robot dog assembly. In addition to assembly, Lens Technology will also become a major component supplier for DOBOT.
Related Articles

SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.
SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.

RECOMMEND

SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025

Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025

National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025


